TRIPLE RECEPTOR AGONIST / METABOLIC RESEARCH
Retatrutide (LY3437943) is an investigational peptide agonist of the GIP, GLP-1, and glucagon receptors. Human clinical trials have examined its effects on body weight, metabolic measures, and safety, with larger clinical-development programs continuing to evaluate its efficacy and longer-term profile.
PRIMARY RESEARCH AREAS
GIP receptor signaling; GLP-1 receptor signaling; glucagon receptor signaling; obesity and body-weight regulation; glucose metabolism; metabolic physiology
EVIDENCE LEVEL
Randomized human clinical-trial evidence exists, including phase 2 studies; broader efficacy, safety, and long-term clinical outcomes continue to be investigated.
Retatrutide differs mechanistically from single- and dual-receptor incretin agonists because it was designed to activate three hormone receptors: GIP, GLP-1, and glucagon.
Retatrutide, also known by the development identifier LY3437943, is an investigational triple-receptor agonist targeting the GIP receptor, GLP-1 receptor, and glucagon receptor.
Combining these signaling pathways is scientifically interesting because each receptor contributes differently to nutrient-responsive endocrine and metabolic physiology. Retatrutide should not be reduced to a single-pathway description.
Metabolic pharmacology has progressed from single-receptor GLP-1 agonism to dual GIP/GLP-1 agonism and then experimental triple-receptor agonism. Retatrutide was developed within this broader effort to study combined hormonal signaling.
Glucagon-receptor activity has been hypothesized to influence energy expenditure and substrate metabolism, while GIP and GLP-1 signaling influence appetite, glucose regulation, and related pathways. These mechanisms are research hypotheses and should be distinguished from demonstrated clinical outcomes.
GIP receptor: GIP participates in nutrient-responsive endocrine signaling and can influence insulin secretion. GLP-1 receptor: GLP-1 signaling contributes to glucose-dependent insulin signaling, glucagon regulation, gastric physiology, and appetite-related signaling.
Glucagon receptor: glucagon signaling participates in hepatic glucose regulation and lipid and substrate metabolism, with proposed effects on energy expenditure. The pharmacology of retatrutide reflects simultaneous activity across these receptor systems and cannot be reduced to one pathway.
In a randomized, double-blind, placebo-controlled phase 2 obesity trial published in 2023, 338 adults participated over 48 weeks. Retatrutide produced dose-dependent reductions in body weight in that specific study.
At 48 weeks, mean body-weight change was approximately -24.2% in the 12-mg group and approximately -2.1% with placebo; higher-dose groups also showed substantial weight reductions. These are results from the study population and trial design, not guaranteed outcomes.
Gastrointestinal adverse events were the most commonly reported adverse events. Dose-dependent increases in heart rate were observed, peaking around 24 weeks and declining thereafter.
Published trial durations are limited relative to lifelong metabolic disease. Larger and longer-term studies are needed to clarify long-term cardiovascular outcomes, safety, durability of weight change, outcomes after discontinuation, comparative effectiveness, and effects across different populations.
The clinical implications of glucagon-receptor activation also remain an active research question. Impressive phase 2 results do not resolve these longer-term questions.
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972.
References were reviewed against primary-source or PubMed records. Trial findings are described as study-specific results rather than established long-term outcomes.
The evidence base includes receptor-pharmacology rationale, preclinical work, and randomized human clinical research. The strongest cited clinical evidence in this profile is the 48-week phase 2 obesity trial.
CELLULAR / IN-VITRO EVIDENCE
Preclinical and mechanistic evidence helps explain three-receptor pharmacology and its rationale. It cannot establish the full range of long-term human clinical outcomes.
ANIMAL / PRECLINICAL EVIDENCE
Preclinical research informs receptor pharmacology and metabolic hypotheses. Such evidence should not be extrapolated directly to humans or presented as clinical fact.
Randomized controlled human evidence exists. In the 48-week phase 2 obesity trial, retatrutide produced dose-dependent body-weight reductions; long-term benefit-risk outcomes remain unresolved.
Established within published research: Retatrutide activates GIP, GLP-1, and glucagon receptors and produced substantial, dose-dependent body-weight reductions in a randomized phase 2 obesity trial.
Not yet established: the long-term benefit-risk profile, long-term cardiovascular outcomes, durability after discontinuation, and the complete clinical implications of triple-receptor agonism.
In the phase 2 obesity trial, gastrointestinal adverse events were commonly reported and were generally dose-related. Dose-dependent increases in heart rate were also observed. Limited-duration studies do not establish a comprehensive long-term safety profile.
Priority research needs include long-term safety, cardiovascular outcomes, durability of weight reduction, maintenance after discontinuation, comparative effectiveness, larger and more diverse study populations, and clarification of the contribution of glucagon-receptor activation to efficacy and adverse effects.
EDITORIALLY REVIEWED
LAST REVIEWED
Research profile reviewed for source accuracy, evidence classification, receptor pharmacology, and distinction between published clinical-trial findings and unresolved long-term outcomes.